Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Novartis AG

APACMed: Johnson & Johnson On Using ‘Big’ For Good In The COVID-19 Challenge

Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

Commercial Medical Device

Moving Cell And Gene Therapies Into Chronic Conditions Depends On Durability, Safety

Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.

Gene Therapy Regenerative Medicine

Advanced Therapies From Orchard & Kite Win EMA Thumbs Up

Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.

Europe Approvals

NICE OKs Sarclisa & Mayzent For Funding In England, But Rejects Vindaqel

The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.

United Kingdom Health Technology Assessment
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Admune Therapeutics
    • Amblyotech, Inc.
    • Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
    • Aspen Japan K.K.
    • Biocine
    • CELLforCURE SASU
    • Chiron Corporation
    • CIBA-GEIGY
    • Corthera Inc.
    • CoStim Pharmaceuticals Inc.
    • ESBATech AG
    • Fougera Pharmaceuticals, Inc.
    • Hexal AG
    • Lek Pharmaceuticals, Inc.
    • Matrix Pharmaceuticals
    • NeuTec Pharma
    • Novartis Groupe France S.A.
    • Novartis Pharmaceuticals
    • Novartis Oncology
    • Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
    • PowerVision, Inc.
    • Protez Pharmaceuticals
    • Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
    • Ebewe Pharma)
    • Selexys Pharmaceuticals Corporation
    • Speedel Holding
    • Spinifex Pharmaceuticals Pty. Ltd.
    • Transcend Medical, Inc.
    • Encore Vision, Inc.
    • Ziarco Group Limited
    • AveXis, Inc.
    • BioLife Cell Bank, Inc.
    • Endocyte, Inc.
    • IFM Tre
    • Zyma SA
    • Annovation Biopharma, Inc.
    • Boxford Subsidiary
    • Curacyte Discovery GmbH
    • Incline Therapeutics, Inc.
    • ProFibrix B.V.
    • Rempex Pharmaceuticals, Inc.
    • Targanta Therapeutics Corporation
    • Tenaxis Medical
    • The Medicines Company
    • Novartis Gene Therapies
UsernamePublicRestriction

Register